COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis - Compare Against 2127.T

Comparison against 2127.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

223.46

Increased from previous period

OCF/share above 1.5x 2127.T's 2.13. David Dodd would verify if a competitive edge drives superior cash generation.

Free Cash Flow per Share

185.38

Increased from previous period

FCF/share above 1.5x 2127.T's 2.09. David Dodd would confirm if a strong moat leads to hefty cash flow.

Capex-to-Operating Cash Flow

17.04%

Increased from previous period

Capex/OCF above 1.5x 2127.T's 2.02%. Michael Burry would suspect an unsustainable capital structure.

Income Quality Ratio (OCF / Net Income)

2.88

Increased from previous period

1.25–1.5x 2127.T's 2.07. Bruce Berkowitz would investigate if the competitor’s accruals hide weaker conversions.

Operating Cash Flow-to-Sales Ratio

13.94%

Increased from previous period

Below 50% of 2127.T's 55.32%. Michael Burry might see a serious concern in bridging sales to real cash.

Select Chart Metric:

3349.T Cash Flow Analysis - Compare Against 2127.T

Comparison against 2127.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Operating Cash Flow per Share

223.46

Increased from previous period

OCF/share above 1.5x 2127.T's 2.13. David Dodd would verify if a competitive edge drives superior cash generation.

Free Cash Flow per Share

185.38

Increased from previous period

FCF/share above 1.5x 2127.T's 2.09. David Dodd would confirm if a strong moat leads to hefty cash flow.

Capex-to-Operating Cash Flow

17.04%

Increased from previous period

Capex/OCF above 1.5x 2127.T's 2.02%. Michael Burry would suspect an unsustainable capital structure.

Income Quality Ratio (OCF / Net Income)

2.88

Increased from previous period

1.25–1.5x 2127.T's 2.07. Bruce Berkowitz would investigate if the competitor’s accruals hide weaker conversions.

Operating Cash Flow-to-Sales Ratio

13.94%

Increased from previous period

Below 50% of 2127.T's 55.32%. Michael Burry might see a serious concern in bridging sales to real cash.

Select Chart Metric: